uric acid has been researched along with canagliflozin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gilbert, RE | 1 |
| Damaraju, CV; Davies, MJ; Meininger, G; Trujillo, A; Vijapurkar, U | 1 |
| Dalama, B; Mesa, J | 1 |
| Atkin, SL; Butler, AE; Katsiki, N; Sahebkar, A; Yaribeygi, H | 1 |
| Abdelrahman, AM; Al Suleimani, Y; Ali, BH; Ashique, M; Manoj, P; Nemmar, A; Shalaby, A | 1 |
| Busslinger, M; Freeman, B; Fu, Y; Huang, W; Koepsell, H; Nespoux, J; Novikov, A; Onishi, A; Patel, R; Vallon, V; van Ginkel, C | 1 |
| Hayashi, J; Kuto, AN; Kutoh, E; Wada, A | 1 |
| Anzai, T; Chikamori, T; Dohi, K; Hisauchi, I; Imai, T; Kamiya, H; Kida, K; Node, K; Sezai, A; Shiina, K; Taguchi, I; Tanaka, A; Tomiyama, H; Toyoda, S | 1 |
3 review(s) available for uric acid and canagliflozin
| Article | Year |
|---|---|
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness | 2016 |
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Disease Progression; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2018 |
1 trial(s) available for uric acid and canagliflozin
| Article | Year |
|---|---|
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Female; Gout; Humans; Hyperuricemia; Hypoglycemic Agents; Incidence; Kidney Calculi; Male; Middle Aged; Risk; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2015 |
4 other study(ies) available for uric acid and canagliflozin
| Article | Year |
|---|---|
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Canagliflozin; Catalase; Cisplatin; Clusterin; Creatinine; Cystatin C; Cytokines; Glutathione Reductase; Kidney; Kidney Diseases; Lipocalin-2; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors; Superoxide Dismutase; Urea; Uric Acid | 2019 |
SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
Topics: Animals; Canagliflozin; Genotype; Glucose Transport Proteins, Facilitative; Kidney Tubules, Proximal; Mice, Inbred C57BL; Mice, Knockout; Organic Anion Transporters; Phenotype; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid; Uricosuric Agents | 2019 |
Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function
.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Humans; Insulin-Secreting Cells; Uric Acid | 2019 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; Humans; Plasma Volume; Stroke Volume; Uric Acid | 2023 |